Clinical Trial Details

Trial ID: L0907
Source ID: IRCT2013122811763N15
Associated Drug: Symbiotic
Title: Effects of Symbiotic on inflammatory markers, liver function, lipid profile, sonographic findings and body composition in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
Acronym: --
Status: Not Recruiting
Study Results: No Results Available
Results: --
Conditions: NAFLD. <br>Fatty (change of) liver;Fatty (change of) liver
Interventions: Intervention 1: Daily oral consumption of Symbiotic supplement produced by Zist takhmir company with Familact commercial name contain 500 mg of seven Probiotic bacteria species and Fructooligosaccharides with below composition for two months: Lactobacillu
Outcome Measures: Fatty liver grade. Timepoint: before and after the intervention. Method of measurement: Ultrasonography.;Alt_Ast. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (blood tests).;Lipid profiles. Timepoint: before and after the intervention. Method of measurement: by laboratory analysis (enzymatic).;Inflammatory markers. Timepoint: before and after the intervention. Method of measurement: Enzyme-Linked Immunosorbent Assay (ELISA).;Body composition. Timepoint: before and after the intervention. Method of measurement: Bioelectrical Impedance Assessment.nan
Sponsor/Collaborators: Vice chancellor for research, Isfahan University of Medical Sciences
Gender: All
Age: 18 years60 years
Phases: Not applicable
Enrollment: 80
Study Type: interventional
Study Designs: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: This study will be a double blind clinical trial. The researcher and the patients will not know that each patient will be
Start Date: 02/01/2014
Completion Date: --
Results First Posted: --
Last Update Posted: 22 February 2018
Locations: Iran (Islamic Republic of)
URL: http://en.irct.ir/trial/11925